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Sublingual Immunotherapy (SLIT). Both contain the allergen
extract from timothy grass (Phleum pratense). The objective of
this analysis was to perform a pharmacoeconomic evaluation
of SLIT with a grass allergy tablet compared to SCIT in both
the Norwegian and Finnish markets. METHODS: A cost-
minimisation approach was deemed appropriate for this evalu-
ation, based on assessments of the alternative’s pharmacokinetic
proﬁles, potential mechanisms of actions and an indirect com-
parison of results from clinical trials. SLIT was judged to
provide at least comparable clinical outcomes to those of SCIT.
Total costs from a societal perspective related to the therapies
were calculated based on national data on resource use and unit
costs. Estimates of resource use were based on guidelines, the
literature and interviews with national clinical specialists.
Resources included the quantities used of the chosen immuno-
therapy, the number of physician visits related to administration
and follow up of the chosen therapy, patient travel and resources
lost due to absence from work in connection with receiving the
therapy. Unit costs were based on national tariffs and wage
statistics. RESULTS: The expected savings in total cost of treat-
ment with SLIT compared to SCIT are approximately 1160 €
and 900 € in Norway and Finland respectively. Alternative sce-
narios and one-way sensitivity analyses indicate the robustness
of the results. CONCLUSION: The result of this cost-
minimisation analysis indicates that for patients with grass
pollen induced rhinoconjunctivitis where immunotherapy is
appropriate, SLIT with a grass allergy tablet is a cost-saving
alternative to SCIT from a societal perspective, both in Norway
and in Finland.
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OBJECTIVES: Asthma patients with severe persistent disease
(GINA Step 4) have the greatest medical need among the asth-
matic population but also consume the highest economic costs.
In our study we have selected severe persistent asthma patients
who have not responded to high-dose antiasthmatic drugs
(inhaled and oral corticosteroids, long-LABA, antileukotrienes
and theophylline). METHODS: In a retrospective setting we
have collected direct and indirect costs for 51 patients (32
women and 19 men) over the period of one year with refractory
asthma in four clinical centres during August to November
2006. RESULTS: The average time from diagnosis was 17.5
years. Two thirds of patients were fully disabled and in rest of
patients working absence was more than 90 days per year.
There was high occurrence of concomitant diagnoses—
hypertension in 37%, osteoporosis in 33% and gastropathy in
31% due to high doses of oral steroids. The mean length of
hospitalization was 11.8 days per year in standard ward and 2.6
days in critical care. Emergency department was visited 8.1
times per year and outpatient departments more than 20
times during the analysed time period. Total direct medical
costs were 4756 EUR/year. Expenditure for hospitalizations was
2320 EUR, outpatient care 374 EUR and emergency care 59
EUR. The cost of asthma medication was 1484 EUR and 226
EUR for other medication. Indirect costs (social and sickness
beneﬁts, productivity loss) were 7262 EUR per year. CONCLU-
SION: The annual total direct plus indirect costs of one patient
with refractory severe persistent asthma were 12018 EUR.
Based on this results there are unmet medical and economic
needs in therapy of this subset of asthma patients in Czech
Republic.
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OBJECTIVES: Compare risk-adjusted costs and patient out-
comes measured by hospitalizations and emergency room visits
in mild persistent asthma patients initiating regular use of inhaled
corticosteroids (ICS), ICS and long acting b2-agonists (LABA), or
leukotriene modiﬁers (LM). METHODS: Study patients, selected
from a privately insured claims database (1999–2005), had at
least one asthma diagnosis; no diagnosis of COPD; mild persis-
tent asthma as deﬁned by the 2005 HEDIS, Leidy’s reliever and
oral steroid methods, and the 2004 GINA guidelines; and initi-
ated regular use of ICS, ICS + LABA or LM. Chi-squared tests
were used for descriptive pairwise comparisons of patient out-
comes. Generalized linear models with log link and gamma dis-
tribution adjusting for patient characteristics were used for
comparisons of total and asthma-related direct costs in the
12-months after the ﬁrst regular study controller use. RESULTS:
The ﬁnal sample included 319 patients with regular use of ICS,
414 patients with ICS + LABA, and 550 patients with LM. There
were no signiﬁcant differences in patient outcomes, as measured
by hospitalizations and emergency room visits (all-cause as well
as asthma-speciﬁc) among the three cohorts. Total risk-adjusted
direct costs were signiﬁcantly lower with ICS and LM compared
with ICS + LABA (ICS: $4305, P = 0.0158 compared with
ICS + LABA; ICS + LABA: $4997, P < 0.0857 compared with
LM; LM: $4562) and not signiﬁcantly different between ICS and
LM. Asthma-related risk-adjusted direct costs were the lowest
with ICS compared with both ICS + LABA and LM (ICS: $782,
P < 0.01 compared with ICS + LABA, P < 0.01 compared with
LM; ICS + LABA: $1126, P < 0.01 compared with LM; LM:
$871). CONCLUSION: Regular ICS use in mild persistent
asthma was associated with lower total direct costs compared
with ICS + LABA and the lowest asthma-related direct costs
compared with ICS + LABA or LM, without any corresponding
difference in patient outcomes.
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OBJECTIVES: As asthma rates increase, questions about the
relationship to residential location have been raised in many
countries. Thus, inpatient and emergency department (ED) care
for adult (age > = 17 years) asthmatics and related costs were
examined by residential location for one year. METHODS: Using
2001–02 Massachusetts data, patients treated for asthma (ICD-9
principal diagnosis code: 493.00–493.92) were identiﬁed. An
encounter proﬁle was established for each patient starting with
the ﬁrst asthma-related stay/visit (index encounter) at any hospi-
tal or ED in 2001, and included all subsequent inpatient and ED
care for asthma within twelve months. Using zip codes, patients
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were classiﬁed by residential location (urban, suburban, rural).
Massachusetts has 351 cities and towns; 10% urban, 19%
rural, and 71% suburban. Hospital charges, adjusted by a
0.517 cost-to-charge ratio, medical inﬂation and geographic
factors are reported in 2007 US$. RESULTS: The cohort
(n = 53,604) had 92,776 asthma-related encounters (65% ED
visits) during the year. The proportion of ED visits for subur-
ban patients was signiﬁcantly (p < 0.05) lower. On average,
rural patients (2%) had 1.7 encounters (range: 1–11), 5.2
asthma-related care days and accrued $5280 per patient. Sub-
urban patients (46%) averaged 1.6 encounters (range: 1–29),
5.5 care days and $9325 per patient. Urban patients (52%) had
1.8 encounters (range: 1–50), 5.9 care days and $8736 per
patient, on average. Over the year, rural patients used 2768
inpatient days and 1582 ED hours accruing $4.9 million in
asthma-related care costs. Suburban patients accrued 66,823
hospital days, 45,954 ED hours and $116.6 million. Urban
patients used 74,359 hospital days and 46,196 ED hours in one
year, accruing $116.1 million. CONCLUSION: Most patients
were from urban locations; however those from suburban areas
had a higher ratio of inpatient stays to ED visits, which con-
tributed to the higher average asthma-related cost per suburban
patient.
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OBJECTIVES: The objective of this study was to compare costs
and effects of montelukast (MON) as add-on to inhaled corti-
costeroids (ICS) with long-acting â2 agonist (LABA) as add-on
to ICS in adult patients with asthma when compliance is taken
into consideration and from a Swedish health care sector per-
spective. METHODS: A health economic model was developed
to calculate the incremental cost utility ratio of MON com-
pared to the LABA salmeterol (SAL). Head-to-head data from
IMPACT, a two-year 48-week clinical study (N = 1490) of
patients with moderate asthma, was used in the model to esti-
mate the relative effectiveness of the two regimens. The relative
compliance for SAL was assumed to be 0.8 vs 1.0 for MON in
the base case scenario. The analysis included costs for drugs,
asthma events and adverse events. Event rates and asthma spe-
ciﬁc quality of life data for MON and SAL treated patients
were collected from the IMPACT trial, while resource utiliza-
tion and unit costs to treat the events were collected from local
sources. RESULTS: In comparison with SAL, MON is associ-
ated with somewhat higher cost, but has, due to similar efﬁcacy
and better compliance, better effectiveness (more prevented
attacks and more QALYs gain), less asthma-related hospitaliza-
tion, and less serious drug-related side effects. The incremental
cost per QALY for MON + ICS compared to SAL + ICS after
adjusting for relative compliance was 7 000 EUR per QALY in
the base case. CONCLUSION: When added to ICS, MON
compared to SAL shows a favorable cost-utility in Sweden.
This conclusion was stable for reasonable variations in the
modelling assumptions.
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OBJECTIVES: Asthma is a major public health problem with
considerable economic impact. The aim of this study was to asses
the extent of uncontrolled disease and associated medical costs in
severe asthma. METHODS: Data were obtained from the
PHARMO Record Linkage System (PHARMO RLS) which
includes drug dispensing and hospitalizations for 2 million sub-
jects in The Netherlands. Severe asthma patients (12–49 years)
were deﬁned as those who had used long-acting beta-agonists
and inhaled corticosteroids for over 200 days and short-acting
beta agonists for at least 100 days in 2004. Uncontrolled asthma
was deﬁned as a hospitalization for asthma or use of multiple,
short (<30 day) courses of oral corticosteroids. Reimbursed costs
of asthma drugs and hospitalizations were calculated. A matched
case-control analyses was performed to compare asthma treat-
ment of cases (hospitalized for asthma or multiple courses of oral
corticosteroids) and controls. RESULTS: A total of 4.7% of
patients receiving at least 2 asthma preparations in the previous
year had severe asthma. A total of 17.4% of these were deﬁned
as having uncontrolled asthma. Excess drug costs for uncon-
trolled asthma with hospitalization were €664 per patient per
year and €282 per patient per year for patients without hospi-
talization. Including hospital admission costs, excess costs were
over €10,000 per patient per year. Lack of control did not seem
to be caused by under-treatment. CONCLUSION: Poor control
of severe asthma leads to disproportionately increased direct
costs compared to controlled severe asthma, especially when
hospital admission is required. Hospitalized patients representing
2% of the patients with severe asthma are responsible for 23% of
the total direct costs.
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OBJECTIVES: It is estimated that over 4.6 million people suffer
from asthma in England and Wales at an estimated annual cost to
the National Health Service (NHS) of more than 889 million.
Beclometasone dipropionate (BDP) is the current mainstay of
inhaled corticosteroid (ICS) therapy for asthma, and approxi-
mately 80% of patients who are prescribed an ICS receive BDP.
However, chloroﬂuorocarbons (CFC), which are used as propel-
lants in the majority of BDP formulations, are now being phased
out in accordance with the Montreal Protocol, a global initiative
to reduce global warming. QVAR (BDP) utilises environmentally
safe hydroﬂuoroalkane (HFA) in its delivery system. It has
equivalent therapeutic effect at about half the daily dose of CFC
BDP due to superior lung penetration. The UK National Institute
for Health and Clinical Excellence (NICE) are currently apprais-
ing a broad number of ICS licensed for the treatment of chronic
asthma. At the time of the enactment of the Montreal Protocol,
when CFC-based BDP will no longer be manufactured, only HFA
based alternatives will be available. We wished to explore the
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